Introduction
Alcohol-associated hepatitis (AH) is a severe liver condition characterized by acute-on-chronic liver injury in patients with chronic alcohol-associated liver disease (ALD). Despite extensive research, effective pharmacologic therapies remain elusive. This article delves into the role of inflammatory cells and mediators in AH pathogenesis and explores potential therapeutic targets.
Pathogenesis of Alcohol-Associated Hepatitis
AH is marked by significant liver inflammation, hepatocyte death, and fibrosis. Chronic alcohol intake leads to liver disorders ranging from simple steatosis to severe conditions like cirrhosis and hepatocellular carcinoma. Approximately 5%-40% of ALD patients develop AH, which is associated with high short-term mortality rates of 20%-50%.
Inflammatory Cells and Mediators
Inflammatory cells, including neutrophils and macrophages, infiltrate the liver in AH patients. These cells release cytokines, chemokines, and other mediators that reshape the liver microenvironment. The crosstalk between inflammatory cells and non-immune cells, such as hepatocytes and hepatic stellate cells (HSCs), plays a crucial role in AH progression.
Advanced Technologies in Characterizing Liver Inflammation
Recent advancements in technologies like single-cell RNA sequencing (scRNA-seq) and multiplex immunostaining have provided deeper insights into liver inflammation in AH. These techniques help identify cell phenotype switches, cell-cell communication, and microenvironment changes in both normal and diseased livers.
Single-Cell RNA Sequencing
scRNA-seq allows for the detailed analysis of individual cell types within the liver, revealing the heterogeneity of immune cells and their roles in AH. This technology has identified key inflammatory pathways and potential therapeutic targets.
Multiplex Immunostaining
This technique enables the simultaneous visualization of multiple targets on a single tissue section, providing a comprehensive view of the inflammatory landscape in AH. It has been instrumental in identifying distinct histopathological phenotypes and the spatial distribution of immune cells.
Potential Therapeutic Targets
Despite extensive research, no effective anti-inflammatory targets have been identified for AH. However, several potential targets have been explored:
IL-8 and Neutrophils
IL-8 is a potent neutrophil chemokine highly upregulated in AH patients. Targeting IL-8 or its receptors (CXCR1/2) could be a promising therapeutic strategy.
Macrophages
Macrophages play dual roles in AH, contributing to both inflammation and tissue repair. Targeting specific inflammatory macrophage populations may offer therapeutic benefits.
Conclusion
Understanding the inflammatory mechanisms in AH is crucial for developing effective therapies. Advanced technologies like scRNA-seq and multiplex immunostaining are paving the way for precision medicine approaches, which may overcome the challenges of treating AH.
References
1. Mackowiak B, Fu Y, Maccioni L, et al. Alcohol-associated liver disease. J Clin Invest 2024.
2. Im GY. Acute alcoholic hepatitis. Clin Liver Dis 2019;23:81–98.
3. Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med 2009;360:2758–2769.
4. Thursz MR, Richardson P, Allison M, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med 2015;372:1619–1628.
5. Gao B, Ahmad MF, Nagy LE, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol 2019;70:249–259.
6. Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers 2018;4:16.
7. Lin P, Yan X, Jing S, et al. Single-cell and spatially resolved transcriptomics for liver biology. Hepatology 2023.
8. Saviano A, Henderson NC, Baumert TF. Single-cell genomics and spatial transcriptomics: discovery of novel cell states and cellular interactions in liver physiology and disease biology. J Hepatol 2020;73:1219–1230.
Authors: Dechun Feng, Seonghwan Hwang, Adrien Guillot, Yang Wang, Yukun Guan, Cheng Chen, Luca Maccioni, Bin Gao